Cardiovascular (CV) Risk Evaluation In Type 2 Diabetes Subjects

GlaxoSmithKline (GSK)

Status: Completed

Conditions: CV Risk; Type 2 Diabetes Mellitus

Study type: Observational

Funder types: Industry

Identifiers

NCT00648284

Avandia OB

104243

Details and patient eligibility

About

The primary objective of this study is to assess the total CV risk in patients with type 2 diabetes and also to assess the impact of rosiglitazone in the total CV risk and the parameters of metabolic syndrome.

Sex: All

Ages: 40 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with diabetes type 2 that their physician has decided to prescribe AVANDIA for better control of their condition
• Have signed informed consent

Exclusion criteria

• Patients with ALT > 2.5x the normal value
• With heart failure symptoms
• With diagnosis of angina pectoris or stable angina demanding continuous treatment with nitrates
• With recent myocardial infarction (<6 months)
• With severe renal disfunction
• Pregnant or lactating or planned to be pregnant during the study
• Under investigational drug treatment
• Alcoholic or drug abuser